Home › Compare › SCRSF vs JNJ

SCRSF vs JNJ: Dividend Comparison 2026

SCRSF yields 100000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SCRSF wins by $4.832206901976048e+26M in total portfolio value
10 years
SCRSF
SCRSF
● Live price
100000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.832206901976048e+26M
Annual income
$482,271,988,201,431,700,000,000,000,000,000.00
Full SCRSF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — SCRSF vs JNJ

📍 SCRSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSCRSFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SCRSF + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
SCRSF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SCRSF
Annual income on $10K today (after 15% tax)
$8,500,000.00/yr
After 10yr DRIP, annual income (after tax)
$409,931,189,971,216,900,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, SCRSF beats the other by $409,931,189,971,216,900,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SCRSF + JNJ for your $10,000?

SCRSF: 50%JNJ: 50%
100% JNJ50/50100% SCRSF
Portfolio after 10yr
$2.416103450988024e+26M
Annual income
$241,135,994,100,715,840,000,000,000,000,000.00/yr
Blended yield
99.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SCRSF
No analyst data
Altman Z
-28.1
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SCRSF buys
0
JNJ buys
0
No recent congressional trades found for SCRSF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSCRSFJNJ
Forward yield100000.00% ✓2.13%
Annual dividend / share$2.00$5.20 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28% ✓
Portfolio after 10y$4.832206901976048e+26M$30.3K ✓
Annual income after 10y$482,271,988,201,431,700,000,000,000,000,000.00 ✓$4,689.40
Total dividends collected$4.8315851896727036e+26M$15.4K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SCRSF vs JNJ ($10,000, DRIP)

YearSCRSF PortfolioSCRSF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,010,700$10,000,000.00$10,592$272.30+$10.00M → SCRSF
2$9,366,505,842$9,355,794,392.52$11,289$357.73+$9366.49M → SCRSF
3$8,191,091,111,834$8,181,068,950,583.78$12,123$472.89+$8191091.10M → SCRSF
4$6,695,134,751,499,451$6,686,370,284,009,789.00$13,141$629.86+$6695134751.49M → SCRSF
5$5,114,850,040,116,031,000$5,107,686,245,931,928,000.00$14,408$846.81+$5114850040116.02M → SCRSF
6$3,652,290,278,277,141,000,000$3,646,817,388,734,216,400,000.00$16,021$1,151.60+$3652290278277141.00M → SCRSF
7$2,437,583,176,648,375,000,000,000$2,433,675,226,050,619,000,000,000.00$18,122$1,588.22+$2437583176648375296.00M → SCRSF
8$1,520,612,508,079,010,700,000,000,000$1,518,004,294,079,997,000,000,000,000.00$20,930$2,228.20+$1.5206125080790106e+21M → SCRSF
9$886,637,379,601,106,600,000,000,000,000$885,010,324,217,461,900,000,000,000,000.00$24,792$3,191.91+$8.866373796011065e+23M → SCRSF
10$483,220,690,197,604,800,000,000,000,000,000$482,271,988,201,431,700,000,000,000,000,000.00$30,274$4,689.40+$4.832206901976048e+26M → SCRSF

SCRSF vs JNJ: Complete Analysis 2026

SCRSF — Stock

Justera Health Ltd., together with its subsidiaries, operates as a health and wellness management company in Canada. The company operates GoStop, a COVID-19 digital testing platform; and provides COVID-19 screening services to businesses and government organizations. It also operates Juillet Wellness Spas, a full-service wellness centre, that provides skincare, medical grade facials, physiotherapy, body massages, registered massage therapy, acupuncture, and laser hair removal services; and distributes TonyMoly skin care products. In addition, the company offers health supplements, protein products, beauty, and pet care solutions; and provides concierge medical services, including urgent concierge medical care, IV vitamin therapy, medical advisory, and preventive screenings to determine the presence or absence of disease. Justera Health Ltd. was founded in 2020 and is headquartered in Toronto, Canada.

Full SCRSF Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this SCRSF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SCRSF vs SCHDSCRSF vs JEPISCRSF vs OSCRSF vs KOSCRSF vs MAINSCRSF vs ABBVSCRSF vs MRKSCRSF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.